Higher H6PD mRNA levels indicated higher survival in triple-negative cases, whereas higher AGR2 levels correlated with worse outcomes in both triple-negative and HER2-enriched cancers (Additional Fig. 3). This evidence concerns the gene ERBB2 and cancer.